Acute myeloid leukemia transformed to a targetable disease

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Korn C, Méndez-Ferrer S. Myeloid malignancies and the microenvironment. Blood 129(7), 811–822 (2017).
  Medline CASGoogle Scholar
• 2. Appelbaum FR, Gundacker H, Head DR et al. Age and acute myeloid leukemia. Blood 107(9), 3481–3485 (2006).
  Medline CASGoogle Scholar
• 3. Stein EM, DiNardo CD, Pollyea DA et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood 130(6), 722–731 (2017). •• Of considerable interest because it leads for the approval of enasidenib for the treatment of patients with relapsed/refractory acute myeloid leukemia (AML) harboring IDH2 mutation.
  Medline CASGoogle Scholar
• 4. Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N. Engl. J. Med. 373(12), 1136–1152 (2015). • Summarizes the most important genomics profile and treatment of patients with acute myeloid leukemia.
  MedlineGoogle Scholar
• 5. Walter RB, Estey EH. Management of older or unfit patients with acute myeloid leukemia. Leukemia 29(4), 770–775 (2015).
  Medline CASGoogle Scholar
• 6. Rosenblat TL, McDevitt MR, Mulford DA et al. Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia. Clin. Cancer Res. 16(21), 5303–5311 (2010).
  Medline CASGoogle Scholar
• 7. Oran B, Weisdorf DJ. Survival for older patients with acute myeloid leukemia: a population-based study. Haematologica 97(12), 1916–1924 (2012).
  MedlineGoogle Scholar
• 8. Pemmaraju N, Kantarjian H Andreeff M, Cortes J, Ravandi F. Investigational FMS-like tyrosine kinase 3 (FLT3) inhibitors in treatment of acute myeloid leukemia (AML). Expert Opin. Investig. Drugs 23(7), 943–954 (2014).
  Medline CASGoogle Scholar
• 9. DiNardo CD, Stein EM, de Botton S et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N. Engl. J. Med. 378(25), 2386–2398 (2018). •• Of considerable interest because it leads for the approval of ivosidenib for the treatment of relapsed/refractory isocitrate dehydrogenase 1-mutant AML.
  Medline CASGoogle Scholar
• 10. Wei AH, Tiong IS. Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin and venetoclax bring new hope to AML. Blood 130(23), 2469–2474 (2017).
  Medline CASGoogle Scholar
• 11. Bross PF, Beitz J, Chen G et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin. Cancer Res. 7(6), 1490–1496 (2001).
  Medline CASGoogle Scholar
• 12. Linenberger ML. CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance. Leukemia 19(2), 176–182 (2005).
  Medline CASGoogle Scholar
• 13. Duong HK, Sekeres MA. Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin. Clin. Interv. Aging 4, 197–205 (2009).
  Medline CASGoogle Scholar
• 14. Larson RA, Sievers EL, Stadtmauer EA et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 104(7), 1442–1452 (2005).
  Medline CASGoogle Scholar
• 15. Petersdorf SH, Kopecky KJ, Slovak M et al. A Phase III study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood 121(24), 4854–4860 (2013).
  Medline CASGoogle Scholar
• 16. Castaigne S, Pautas C, Terré C et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, Phase III study. Lancet 379(9825), 1508–1516 (2012). •• Of considerable interest because it leads for the approval of gemtuzumab ozogamicin for the treatment of newly diagnosed AML CD33+.
  Medline CASGoogle Scholar
• 17. Hills RK, Castaigne S, Appelbaum FR et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol. 15(9), 986–996 (2014).
  Medline CASGoogle Scholar
• 18. US FDA. Research C for DE and FDA approves gemtuzumab ozogamicin for CD33-positive AML (2019). www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-gemtuzumab-ozogamicin-cd33-positive-aml
  Google Scholar
• 19. Parcells BW, Ikeda AK, Simms-Waldrip T, Moore TB, Sakamoto KM. FMS-like tyrosine kinase 3 in normal hematopoiesis and acute myeloid leukemia. Stem Cells 24(5), 1174–1184 (2006).
  Medline CASGoogle Scholar
• 20. Fathi AT, Chen YB. The role of FLT3 inhibitors in the treatment of FLT3-mutated acute myeloid leukemia. Eur. J. Haematol. 98(4), 330–336 (2017).
  MedlineGoogle Scholar
• 21. Takahashi S. Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications. J. Hematol. Oncol. 4, 13 (2011).
  Medline CASGoogle Scholar
• 22. Dhillon S. Gilteritinib: first global approval. Drugs 79(3), 331–339 (2019).
  Medline CASGoogle Scholar
• 23. Stone RM, Mandrekar SJ, Sanford BL et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N. Engl. J. Med. 377(5), 454–464 (2017). •• Based on the results of this trial, the US FDA approved midostaurin in combination with chemotherapy for the treatment of newly diagnosed AML with FMS-like tyrosine kinase 3 mutation.
  Medline CASGoogle Scholar
• 24. Short NJ, Kantarjian H, Ravandi F, Daver N. Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia. Ther. Adv. Hematol. 10 (2019). www.ncbi.nlm.nih.gov/pmc/articles/PMC6378516/
  Google Scholar
• 25. Propper DJ, McDonald AC, Man A et al. Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J. Clin. Oncol. 19(5), 1485–1492 (2001).
  Medline CASGoogle Scholar
• 26. Stone RM, Fischer T, Paquette R et al. Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia. Leukemia 26(9), 2061–2068 (2012).
  Medline CASGoogle Scholar
• 27. US FDA. Research C for DE and midostaurin (2019). www.fda.gov/drugs/resources-information-approved-drugs/midostaurin
  Google Scholar
• 28. EMA. Rydapt. (2018). www.ema.europa.eu/en/medicines/human/EPAR/rydapt
  Google Scholar
• 29. Schlenk RF, Weber D, Fiedler W et al. Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD. Blood 133(8), 840–851 (2019).
  Medline CASGoogle Scholar
• 30. Kampa-Schittenhelm KM, Heinrich MC, Akmut F, Döhner H, Döhner K, Schittenhelm MM. Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms. Mol. Cancer 12, 19 (2013).
  Medline CASGoogle Scholar
• 31. Daver N, Schlenk RF, Russell NH, Levis MJ. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia 33(2), 299–312 (2019).
  Medline CASGoogle Scholar
• 32. Cortes JE, Kantarjian H, Foran JM et al. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status. J. Clin. Oncol. 31(29), 3681–3687 (2013).
  Medline CASGoogle Scholar
• 33. Cortes J, Perl AE, Döhner H et al. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, Phase II trial. Lancet Oncol. 19(7), 889–903 (2018).
  Medline CASGoogle Scholar
• 34. Cortes JE, Tallman MS, Schiller GJ et al. Phase IIb study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML. Blood 132(6), 598–607 (2018).
  Medline CASGoogle Scholar
• 35. Cortes JE, Khaled S, Martinelli G et al. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, Phase III trial. Lancet Oncol. 20(7), 984–997 (2019).
  Medline CASGoogle Scholar
• 36. Zimmerman EI, Turner DC, Buaboonnam J et al. Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia. Blood 122(22), 3607–3615 (2013).
  Medline CASGoogle Scholar
• 37. Galanis A, Ma H, Rajkhowa T et al. Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants. Blood 123(1), 94–100 (2014).
  Medline CASGoogle Scholar
• 38. Cortes JE, Kantarjian HM, Kadia TM et al. Crenolanib besylate, a type I pan-FLT3 inhibitor, to demonstrate clinical activity in multiply relapsed FLT3-ITD and D835 AML. JCO 34(Suppl. 15), 7008–7008 (2016).
  Google Scholar
• 39. Goldberg AD, Coombs CC, Wang ES et al. Younger patients with newly diagnosed FLT3-mutant AML treated with crenolanib plus chemotherapy achieve adequate free crenolanib levels and durable remissions. Blood 134(Suppl. 1), 1326–1326 (2019).
  Google Scholar
• 40. Mori M, Kaneko N, Ueno Y et al. Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia. Invest. New Drugs 35(5), 556–565 (2017).
  Medline CASGoogle Scholar
• 41. Lee LY, Hernandez D, Rajkhowa T et al. Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor. Blood 129(2), 257–260 (2017).
  Medline CASGoogle Scholar
• 42. Neubauer A, Fiebeler A, Graham DK et al. Expression of axl, a transforming receptor tyrosine kinase, in normal and malignant hematopoiesis. Blood 84(6), 1931–1941 (1994).
  Medline CASGoogle Scholar
• 43. Perl AE, Altman JK, Cortes J et al. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, Phase I-2 study. Lancet Oncol. 18(8), 1061–1075 (2017).
  Medline CASGoogle Scholar
• 44. Perl AE, Martinelli G, Cortes JE et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N. Engl. J. Med. 381(18), 1728–1740 (2019). •• Shows the efficacy of gilteritinib in comparison with chemotherapy for the treatment of relapsed/refractory AML.
  Medline CASGoogle Scholar
• 45. US FDA. Research C for DE and FDA approves gilteritinib for relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutatation (2018). www.fda.gov/drugs/fda-approves-gilteritinib-relapsed-or-refractory-acute-myeloid-leukemia-aml-flt3-mutatation
  Google Scholar
• 46. Pratz KW, Cherry M, Altman JK et al. Updated results from a Phase I study of gilteritinib in combination with induction and consolidation chemotherapy in subjects with newly diagnosed acute myeloid leukemia (AML). Blood 132(Suppl. 1), 564–564 (2018).
  Google Scholar
• 47. Dang L, White DW, Gross S et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462(7274), 739–744 (2009).
  Medline CASGoogle Scholar
• 48. Figueroa ME, Lugthart S, Li Y et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 17(1), 13–27 (2010).
  Medline CASGoogle Scholar
• 49. US FDA. Research C for DE and FDA approves ivosidenib for relapsed or refractory acute myeloid leukemia (2019). www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ivosidenib-relapsed-or-refractory-acute-myeloid-leukemia
  Google Scholar
• 50. Dinardo CD, Stein AS, Stein EM et al. Mutant IDH1 inhibitor ivosidenib (IVO; AG-120) in combination with azacitidine (AZA) for newly diagnosed acute myeloid leukemia (ND AML). JCO 37(Suppl. 15), 7011–7011 (2019).
  Google Scholar
• 51. US FDA. Research C for DE and FDA approves ivosidenib as first-line treatment for AML with IDH1 mutation (2019). www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ivosidenib-first-line-treatment-aml-idh1-mutation
  Google Scholar
• 52. Stein EM, DiNardo CD, Mims AS et al. Ivosidenib or enasidenib combined with standard induction chemotherapy is well tolerated and active in patients with newly diagnosed AML with an IDH1 or IDH2 mutation: initial results from a Phase I trial. Blood 130(Suppl. 1), 726–726 (2017).
  Google Scholar
• 53. US FDA. Research C for DE and FDA granted regular approval to enasidenib for the treatment of relapsed or refractory AML (2019). www.fda.gov/drugs/resources-information-approved-drugs/fda-granted-regular-approval-enasidenib-treatment-relapsed-or-refractory-aml
  Google Scholar
• 54. Stein EM, DiNardo CD, Fathi AT et al. Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. Blood 133(7), 676–687 (2019).
  Medline CASGoogle Scholar
• 55. Pollyea DA, Tallman MS, de Botton S et al. Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia. Leukemia 11, 2575–2584 (2019).
  Google Scholar
• 56. Fathi AT, DiNardo CD, Kline I et al. Differentiation syndrome associated with enasidenib, a selective inhibitor of mutant isocitrate dehydrogenase 2: analysis of a Phase I/II study. JAMA Oncol. 4(8), 1106–1110 (2018).
  MedlineGoogle Scholar
• 57. Norsworthy KJ, Luo L, Hsu V et al. FDA approval summary: ivosidenib for relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-1 mutation. Clin. Cancer Res. 25(11), 3205–3209 (2019).
  Medline CASGoogle Scholar